Abstract: A method for testing a software defined network (SDN) including a plurality of equipment, including: selecting a test case, wherein the test case includes a test step to be performed on an equipment of the SDN and wherein the test step includes a template logical indicator and a variable file logical indicator; executing the test case including obtaining a network definition for the SDN, obtaining a template for the equipment in the SDN to be tested indicated by the template logical indicator at run time, populating variable values in the obtained template using variable values from a variable file indicated by the variable file logical indicator at run time, and executing a first test step indicated in the template using the populated variable values.

Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for lowering blood pressure levels.

Abstract: A communications network is described wherein a plurality of devices are assigned unique identifiers and configured to communication with the network, and wherein servers on the edge of the network are configured to control the devices using the unique identifiers. The devices can be controlled according to rules defined by a user, and the devices may be configured to communicate with and control other devices in the network.

Abstract: The present invention relates to novel C-terminal truncated fragments and novel N-terminal modified analogues of gastric inhibitory polypeptide as well as various GIP analogues with a reduced peptide bond or alterations of the amino acids close to the dipeptidyl peptidase IV (DPIV)-specific cleavage site providing improved DPIV-resistance and prolonged half-life. Further the invention relates to novel analogs with different linkers between potential receptor binding sites of GIP. The compounds of the present invention and their pharmaceutically acceptable salts are useful in treating GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.

Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for lowering blood pressure levels.

Abstract: The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to increase the half-life of incretins in vivo.